MDM2 PROTAC Compounds for Targeted Protein Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing small molecule drugs face challenges in targeting protein-protein interactions, particularly with E3 ubiquitin ligases like MDM2, which are crucial for modulating proteins such as p53, leading to non-specific effects and inability to effectively target a wide range of proteins for cancer treatment.
Innovation Solution
Development of bifunctional compounds, known as PROTACs, that recruit target proteins to E3 ubiquitin ligases like MDM2 for degradation, using moieties that bind both the ligase and the target protein, allowing for specific ubiquitination and degradation of various proteins.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule drugs are used to target protein-protein interactions with E3 ubiquitin ligases, then therapeutic effects can be achieved, but specificity is reduced and side effects increase
Solution Approach 1:
The bifunctional compound is divided into two distinct functional moieties: an E3 ligase binding moiety that specifically binds to the E3 ubiquitin ligase, and a target protein binding moiety that specifically binds to the target protein. This segmentation allows each moiety to independently recognize its binding partner, enabling highly specific recruitment of the target protein to the E3 ligase without off-target effects.
2Adaptability or versatility
If small molecule drugs are used to target protein-protein interactions, then binding can be achieved, but the ability to target a wide range of proteins is limited
Solution Approach 1:
The bifunctional compound design creates a universal platform where the E3 ligase binding moiety serves as a constant functional element that recruits various target proteins through different target protein binding moieties. This multi-functional design allows a single E3 ligase binder to be paired with multiple different target protein ligands, enabling broad targeting capability across diverse protein classes including kinases, transcription factors, and nuclear hormone receptors.
3Reliability
If conventional small molecule inhibitors are used, then enzyme activity can be inhibited, but degradation of target proteins cannot be achieved
Solution Approach 1:
The bifunctional compound acts as an intermediary that bridges the E3 ubiquitin ligase and the target protein, facilitating their interaction. By recruiting the target protein to the E3 ligase through this intermediary compound, the system enables ubiquitination and subsequent proteasomal degradation of the target protein, achieving a level of efficacy beyond simple inhibition.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables broad pharmacological activities by degrading a wide range of proteins, including kinases, transcription factors, and nuclear hormone receptors, providing a therapeutic approach for diseases like cancer with enhanced specificity and reduced side effects.
Implementation Method 1
bifunctional compounds which function to recruit endogenous proteins to an E3 ubiquitin ligase for degradation
Implementation Method 2
confer substrate specificity for ubiquitination
Implementation Method 3
degraded and/or otherwise inhibited by bifunctional compounds
Data Source
AI summary
The description relates to MDM2 binding compounds, including bifunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the description provides compounds, which contain on one end a ligand which binds to the MDM2 E3 ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. Compounds can be synthesized that exhibit a broad range of pharmacological activities consistent with the degradation/inhibition of targeted polypeptides of nearly any type.